The new facility will expand the company’s existing footprint in the region while adding additional local production of several technologies including Aptar’s pressurized metered dose inhaler (pMDI) valve, as well as breath-actuated devices and single-dose nasal sprays.
Aptar is the world’s leading provider of inhalation devices, which are critical for delivery of the drugs used to treat respiratory diseases such as asthma and COPD. The company is helping Indian pharmaceutical companies in launching inhalers and nasal sprays domestically and for export markets.
The new Taloja plant will also enable Aptar to meet the region’s growing needs by adding an additional 4400 square metres of manufacturing footprint and will be constructed adjacent to the existing Aptar Mumbai facility that opened in 2023.
“This additional plant in Taloja will further strengthen our ability to efficiently deliver high-quality, innovative products and reinforces our commitment to investing in the pharma end markets,” said said Sanjay Kapote, President of Aptar Pharma India and Southeast Asia, commented,
“Additionally, we are keen on exploring acquisitions in the pharma space. We see significant growth potential within the pharmaceutical industry in India and the potential to expand our position in the market,” Kapote added.Aptar is looking for potential acquisitions and partnerships with IP driven, pharma packaging companies to continue the expansion of their drug dosing, dispensing and protection offerings.
